NOVARTIS drug Zortress has
become the first in over a decade
to be approved by US Food and
Drug Administration to prevent
organ rejection in adult liver
transplant patients.
Zortress (everolimus) is also is the
first mammalian target of
rapamycin (mTOR) inhibitor
approved for use following liver
transplantation.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Feb 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Feb 13
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.